Efficacy and Safety Assessment of T2345 in Ocular Hypertensive or Glaucomatous Patients

Phase 3CompletedNCT01156012

Laboratoires Thea404 enrolled

Overview

The purpose of this study is to assess the efficacy and safety of T2345 versus active comparator.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

SINGLE

Enrollment

404

Conditions

Glaucoma

Interventions

T2345DRUG

One drop of T2345

ProstaglandinDRUG

One drop

Eligibility

Sex: ALLMin age: 18 YearsMax age: 90 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Adult patients diagnosed with glaucoma Exclusion Criteria: * Under 18.

Locations (1)

Medical Director

Clermont-Ferrand, France

Outcomes

Primary Outcomes

Change From Baseline in Intraocular Pressure (IOP)

The worse eye is defined as: * If both eyes are eligible the eye with highest Intraocular pressure (IOP) at Day 0 (D0). If both eyes have the same IOP at D0 the worse eye is the right eye. * If only one eye is eligible this eye is the worse eye. * If neither eye is eligible the worse eye is defined as the eye with the highest IOP at D0. If both eyes have the same IOP at D0 the worse eye is the right eye.

Time frame: Day 0 and Day 84

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.